Simtuzumab trial (RAINIER, Gilead sponsored) is actively recruiting.
In brief, the study is a multicenter, phase 2 randomized, double-blind, placebo-controlled trial of a subcutaneous LOXL2 monoclonal antibody in patients with Idiopathic Pulmonary Fibrosis (IPF) up to 180 weeks.
Roel will be screening clinics to look for potentially suitable candidates but would contact you to check if contacting the patient would be acceptable.
If you have a patient who might be interested in the study, please contact Roel Almario with the patient’s name and MRN , so he may discuss the study with the patient.
We will be reviewing any possible cases in Multidisciplinary ILD conference (there is also a central review process once patients have signed informed consent.)
Please let me know if you have any questions.
Thank you,
Krishna Thavarajah
Krishna Thavarajah, MD MS
Medical Director, Pulmonary Clinics
Director, Interstitial Lung Disease Program
Division of Pulmonary and Critical Care Medicine
Henry Ford Hospital
Clinical Assistant Professor
Wayne State University School of Medicine